title: Recent trends in product development and regulatory issues on impurities in active pharmaceutical ingredient (API) and drug products. Part 2: Safety considerations of impurities in pharmaceutical products and surveying the impurity landscape.
authors.affiliation: Pfizer Global Research and Development, Groton, Connecticut, USA.
authors.forename: Karen M
authors.initials: KM
authors.lastname: Alsante
authors.forename: Kim C
authors.initials: KC
authors.lastname: Huynh-Ba
authors.forename: Steven W
authors.initials: SW
authors.lastname: Baertschi
authors.forename: Robert A
authors.initials: RA
authors.lastname: Reed
authors.forename: Margaret S
authors.initials: MS
authors.lastname: Landis
authors.forename: Scott
authors.initials: S
authors.lastname: Furness
authors.forename: Bernard
authors.initials: B
authors.lastname: Olsen
authors.forename: Mark
authors.initials: M
authors.lastname: Mowery
authors.forename: Karen
authors.initials: K
authors.lastname: Russo
authors.forename: Robert
authors.initials: R
authors.lastname: Iser
authors.forename: Gregory A
authors.initials: GA
authors.lastname: Stephenson
authors.forename: Patrick
authors.initials: P
authors.lastname: Jansen
mesh_terms: D004340:Drug Contamination; D055808:Drug Discovery; D004364:Pharmaceutical Preparations; D012449:Safety
chemical_list: D004364:Pharmaceutical Preparations